Bulletin
Investor Alert

New York Markets Close in:

Gilead Sciences Inc.

NAS: GILD

GO
/marketstate/country/us

Countdown to close

 --Real time quotes

Oct 20, 2021, 3:22 p.m.

/zigman2/quotes/210293917/composite

$

67.03

Change

+0.13 +0.19%

Volume

Volume 2.86m

Real time quotes

/zigman2/quotes/210293917/composite

Previous close

$ 66.90

$ 67.03

Change

+0.13 +0.19%

Day low

Day high

$66.81

$67.31

Open

52 week low

52 week high

$56.56

$73.34

Open

Company Description

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology,...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Valuation

P/E Current

686.93

P/E Ratio (with extraordinary items)

16.33

P/E Ratio (without extraordinary items)

598.15

Price to Sales Ratio

2.99

Price to Book Ratio

4.01

Price to Cash Flow Ratio

9.01

Enterprise Value to EBITDA

8.11

Enterprise Value to Sales

3.95

Total Debt to Enterprise Value

0.33

Efficiency

Revenue/Employee

1,811,912.00

Income Per Employee

9,044.00

Receivables Turnover

5.81

Total Asset Turnover

0.38

Liquidity

Current Ratio

1.40

Quick Ratio

1.26

Cash Ratio

0.72

Profitability

Gross Margin

81.70

Operating Margin

42.38

Pretax Margin

6.77

Net Margin

0.50

Return on Assets

0.19

Return on Equity

0.60

Return on Total Capital

21.25

Return on Invested Capital

0.27

Capital Structure

Total Debt to Total Equity

176.45

Total Debt to Total Capital

63.83

Total Debt to Total Assets

46.95

Long-Term Debt to Equity

160.71

Long-Term Debt to Total Capital

58.14

Officers and Executives

Name Age Officer Since Title
Mr. Daniel P. O'Day 55 2019 Chairman & Chief Executive Officer
Mr. Andrew D. Dickinson 49 2016 Chief Financial Officer
Dr. Merdad V. Parsey - 2019 Chief Medical Officer
Dr. Flavius Martin - 2021 Executive Vice President-Research
Ms. Johanna Mercier 50 2019 Chief Commercial Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/17/2021 Diane E. Wilfong
SVP, Controller & CAO
13,610   Disposition at $72.5 per share. 986,725
08/17/2021 Diane E. Wilfong
SVP, Controller & CAO
3,829   Derivative/Non-derivative trans. at $66.36 per share. 254,092
08/17/2021 Diane E. Wilfong
SVP, Controller & CAO
9,781   Derivative/Non-derivative trans. at $68.75 per share. 672,443
08/15/2021 Andrew D. Dickinson
Chief Financial Officer
1   Award at $55.08 per share. 55
08/15/2021 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
32   Award at $55.08 per share. 1,762
08/15/2021 Merdad V. Parsey
Chief Medical Officer
1   Award at $55.08 per share. 55
08/10/2021 Diane E. Wilfong
SVP, Controller & CAO
907   Derivative/Non-derivative trans. at $69.24 per share. 62,800
08/10/2021 Diane E. Wilfong
SVP, Controller & CAO
2,480   Derivative/Non-derivative trans. at $0 per share. 0
07/24/2021 Johanna Mercier
Chief Commercial Officer
3,425   Derivative/Non-derivative trans. at $69.02 per share. 236,393
07/24/2021 Johanna Mercier
Chief Commercial Officer
7,505   Derivative/Non-derivative trans. at $0 per share. 0
06/15/2021 Javier J. Rodriguez
Director
1,838   Derivative/Non-derivative trans. at $0 per share. 0
06/10/2021 Andrew D. Dickinson
Chief Financial Officer
1,605   Derivative/Non-derivative trans. at $69.29 per share. 111,210
06/10/2021 Andrew D. Dickinson
Chief Financial Officer
3,646   Derivative/Non-derivative trans. at $0 per share. 0
05/06/2021 Per Wold-Olsen
Director
1,936   Derivative/Non-derivative trans. at $0 per share. 0
05/06/2021 Richard J. Whitley
Director
1,936   Derivative/Non-derivative trans. at $0 per share. 0
05/06/2021 Jacqueline K. Barton
Director
1,936   Derivative/Non-derivative trans. at $0 per share. 0
05/06/2021 Harish M. Manwani
Director
1,936   Derivative/Non-derivative trans. at $0 per share. 0
05/04/2021 Johanna Mercier
Chief Commercial Officer
19,496   Disposition at $66.09 per share. 1,288,490
05/03/2021 Richard J. Whitley
Director
20,282   Disposition at $64.57 per share. 1,309,608
05/03/2021 Richard J. Whitley
Director
20,282   Derivative/Non-derivative trans. at $20.64 per share. 418,620
03/11/2021 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
1,486   Disposition at $63.36 per share. 94,152
/news/latest/company/us/gild

MarketWatch News on GILD

  1. AstraZeneca PLC ADR outperforms competitors on strong trading day

    4:38 p.m. Oct. 19, 2021

    - MarketWatch Automation

  2. Gilead Sciences Inc. stock falls Monday, underperforms market

    4:56 p.m. Oct. 18, 2021

    - MarketWatch Automation

  3. AstraZeneca PLC ADR falls Monday, underperforms market

    4:38 p.m. Oct. 18, 2021

    - MarketWatch Automation

  4. Gilead Sciences Inc. stock underperforms Friday when compared to competitors

    4:56 p.m. Oct. 15, 2021

    - MarketWatch Automation

  5. AstraZeneca PLC ADR outperforms competitors on strong trading day

    4:38 p.m. Oct. 15, 2021

    - MarketWatch Automation

  6. Gilead Sciences Inc. stock rises Thursday, still underperforms market

    4:56 p.m. Oct. 14, 2021

    - MarketWatch Automation

  7. AstraZeneca PLC ADR underperforms Thursday when compared to competitors

    4:38 p.m. Oct. 14, 2021

    - MarketWatch Automation

  8. Gilead Sciences Inc. stock outperforms market on strong trading day

    4:56 p.m. Oct. 13, 2021

    - MarketWatch Automation

  9. AstraZeneca PLC ADR rises Wednesday, still underperforms market

    4:38 p.m. Oct. 13, 2021

    - MarketWatch Automation

  10. Gilead Sciences Inc. stock outperforms competitors despite losses on the day

    4:56 p.m. Oct. 12, 2021

    - MarketWatch Automation

  11. AstraZeneca PLC ADR falls Tuesday, underperforms market

    4:38 p.m. Oct. 12, 2021

    - MarketWatch Automation

  12. Gilead Sciences Inc. stock rises Monday, outperforms market

    4:56 p.m. Oct. 11, 2021

    - MarketWatch Automation

  13. AstraZeneca PLC ADR rises Monday, outperforms market

    4:39 p.m. Oct. 11, 2021

    - MarketWatch Automation

  14. AstraZeneca PLC ADR outperforms market on strong trading day

    4:38 p.m. Oct. 8, 2021

    - MarketWatch Automation

  15. Merck’s Covid Pill Could Pose Serious Risks, Scientists Warn

    9:30 p.m. Oct. 8, 2021

    - Barron's Online

  16. Gilead Sciences Inc. stock outperforms market on strong trading day

    4:55 p.m. Oct. 7, 2021

    - MarketWatch Automation

  17. Loading more headlines...
/news/nonmarketwatch/company/us/gild

Other News on GILD

  1. 3 Under-the-Radar COVID Stocks

    8:00 a.m. Today

    - Motley Fool

  2. Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

    11:27 a.m. Oct. 18, 2021

    - Zacks.com

  3. 2 Tricks and a Treat for Gene Therapy Investors

    6:45 a.m. Oct. 18, 2021

    - Motley Fool

  4. 2 Top Healthcare Stocks That Could Be Bought Out in 2022

    7:00 a.m. Oct. 16, 2021

    - Motley Fool

  5. IBB: Healthcare Dashboard For October

    8:24 p.m. Oct. 14, 2021

    - Seeking Alpha

  6. Jackson, Grant Investment Advisers, Inc. Buys Global X U.S. ...

    12:38 p.m. Oct. 13, 2021

    - GuruFocus.com

  7. Why CRISPR Therapeutics Stock Is Sinking Today

    10:52 a.m. Oct. 13, 2021

    - Motley Fool

  8. 5 High-Yield Stocks Trading Below GF Value

    5:00 p.m. Oct. 12, 2021

    - GuruFocus.com

  9. Loading more headlines...

At a Glance

Gilead Sciences, Inc.

333 Lakeside Drive

Foster City, California 94404

Phone

1 6505743000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$24.64B

Net Income

$123.00M

2020 Sales Growth

10.4%

Employees

13,600

/news/pressrelease/company/us/gild

Press Releases on GILD

  1. Gilead Sciences Announces Second Quarter 2021 Financial Results

    4:01 p.m. July 29, 2021

    - BusinessWire - BZX

  2. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/203240833/composite ASG-0.56%
  • /zigman2/quotes/200272047/composite OI-1.52%
  • /zigman2/quotes/201842100/composite DISCK-2.18%
  • /zigman2/quotes/208424563/composite GRFS-2.16%
  • /zigman2/quotes/202258849/composite COOP+2.03%
X
Powered by StockTwits
Link to MarketWatch's Slice.